pharma · Glioblastoma · Unresectable or metastatic soft tissue sarcoma
Philogen
Philogen S.p.A.
Philogen S.p.A is a pharma organization headquartered in SIENA, IT. Primary therapeutic focus areas include Glioblastoma, Unresectable or metastatic soft tissue sarcoma, Cutaneous Squamous Cell Carcinoma, locally advance
Company details
- Status
- Public
- HQ
- Loc. Bellaria, 35, Sovicille, SIENA 53018, IT
- Founded
- 1996
- Employees
- 180
- Programs
- 18
- Drugs
- 29
- Patents
- 0
Darleukin, Fibromun
Phase 3 · small molecule · Malignant melanoma of the skin in patients with locally advanced and fully resectable melanoma with/without prior therapy and presence of injectable cutaneous and/or subcutaneous or nodal lesions
Darleukin, Fibromun for Malignant melanoma of the skin in patients with locally advanced and fully resectable melanoma with/without prior therapy and presence of injectable cutaneous and/or subcutaneous or nodal lesions is a Phase 3 program (small_molecule) at Philogen S.p.A. with 1 ClinicalTrials.gov record(s).
Internal code PH-L19IL2TNF-02/15
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Philogen S.p.A.
- Phase
- Phase 3
- Modality
- small_molecule
- Indication
- Malignant melanoma of the skin in patients with locally advanced and fully resectable melanoma with/without prior therapy and presence of injectable cutaneous and/or subcutaneous or nodal lesions
- Status
- active
- Trials
- 1